Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
Russell Pachynski, MD
Advertisement
Articles by Russell Pachynski, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5